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420ABSTRACT
Background. Nonadherence to immunosuppressive therapy contributes to the loss of
grafts. One of the problem is the fractioning of immunosuppressive dose. In fact, it was
demonstrated that a single daily dose (QD) is associated with an increased adherence to
therapy compared with twice daily dosing (BID). Tacrolimus (TAC), calcineurin inhibitor,
is one of immunosuppression pillar in organ transplantation and its action is strongly
correlated with blood concentration and therefore the therapeutic drug monitoring is
recommended in the guidelines. However, one of the critical points of TAC is the poor and
variable bioavailability that inﬂuences immunosuppression, and is also responsible for
adverse effects.
Methods. MeltDose Technology is a new technology to improve efﬁcacy and/or reduce
side effects. This new technology applied to TAC (Envarsus or LCP-TAC) has achieved 4
main objectives: (1) improved bioavailability, (2) reduced dose fractioning to one tablet per
day, (3) limited variability concentrations of TAC, and (4) lower doses of TAC will be
administered.
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Udine, Italy. E-mail: massimo.baraldo@uniud.itTACROLIMUS (TAC), calcineurin inhibitor, is a pillarof immunosuppression in organ transplantation and it
has as an immediate release (IR) formulation requiring a
twice daily dose regimen (BID). Its action is associated
strongly with blood concentration and therefore the actual
guidelines recommended therapeutic drug monitoring [1].
One of the critical points of TAC-IR, is the poor and
variable bioavailability [2,3]. Because the maximum drug
concentration (Cmax) and area under the curve (AUC0e12)
are fundamental to immunosuppression, but are also
responsible for adverse effects (nephrotoxicity, tremor and
paresthesia, hypertension, hyperglycemia), these parameters
strongly affect the graft and patient health [4].
A review showing the results of 10 cohort studies con-
ducted on kidney transplants (KTx) indicates that, in
transplant recipients, nonadherence to immunosuppressive
therapy contributes to the loss of grafts. Published data
indicate that it can be up to 36% loss of the graft, a 7-fold
increase compared with compliant patients [5,6].
In KTx, poor adherence to therapy seems to be linked
closely with the dose fractioning of the drug; that is, the
higher the dose fractionation, the lower is the adherence.
Therefore, a single daily dose (QD) is associated with an6
.org/10.1016/j.transproceed.2016.02.002increased adherence to therapy compared with a BID
schedule [7]. So the second type of TAC was a prolonged-
released capsules (TAC-PR) administered as single daily
dose. This new formulation, however, did not solve the
problem of interindividual and intraindividual variability,
which is linked with lesser bioavailability.
Nanotechnology and nanoformulations in medicine can
overcome the problems of poor bioavailability by virtue of
the nanosize of drugs [8]. An extended-release formula-
tion of TAC designed for once-daily administration (LCP-
TAC) is a new prolonged-release TAC formulation, using
a drug delivery technology designed to enhance the
bioavailability of drugs with low water solubility by
creating a solid solution of the drug. This minireview
analyzes the pharmacokinetic properties of LCP-TAC in
transplant recipients, omitting aspects of efﬁcacy and
safety of the new formulation.ª 2016 by Elsevier Inc. All rights reserved.
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MeltDose technology, a platform developed by Veloxis Pharma-
ceuticals A/S (Hørsholm, Denmark), a company founded in 2002, is
a drug delivery technology used to enhance the oral bioavailability
and control the release of a drug, especially low water-soluble or
-insoluble drugs. The goal of this technology is to improve efﬁcacy
and/or reduce side effects. Particle size plays a vital role in
bioavailability. Unlike conventional and nanocrystal drug delivery
formulations, which use larger particles that are more difﬁcult to
absorb, MeltDose technology enhances bioavailability by reducing
the drug to the smallest possible particle size down to single
molecules. The smaller particle size enables better dissolution and
absorption. The particles of the active substance have been reduced
as small as possible, passing from the size of 10 mm of the
conventional drug, to a solution <0.1 mm diameter, to be organized
into oral tablets. Fenoﬁbrate, a lipid-regulating agent to control
cholesterol and marketed as Fenoglide in the United States by
Shore Therapeutics (East Setauket, NY), was the ﬁrst product
approved in the United States using the MeltDose technology [9].
The second application was to TAC (Envarsus or LCP-TAC).
This formulation improves oral bioavailability and reduces the
daily dose by 30% from previous formulations.Fig 1. Mean whole-blood tacrolimus concentration in 47 kidney
transplant patients (KTPs) on day 7, 14, and 21 versus time (A)
and in 44 liver transplant patients (LTPs) on day 7, 14, 21, and
26 versus time (B). Dosage details are shown in paper. Repro-
duced from Gaber et al. [12] and Alloway et al. [13], with
permission.RESULTS
The pharmacokinetic proﬁles of TAC have been recently
studied by Garnok-Jones [10], who compared kidney
transplant recipients (KTRs) and liver transplant recipients
who were stable, treated TAC-IR and converted to LCP-
TAC. The total daily dosage was 5.26 versus 7.39 mg
comparing the LCP-TAC versus TAC-IR with a statistically
signiﬁcant difference in KTRs (P < .05) but not in
LTRs (4.4 vs 6.1 mg). The AUC24 (ng $ h/mL) was
comparable in LCP-TAC and TAC-IR without signiﬁcant
differences (206.7 vs 212.1 ng $ h/mL; in KTRs; 185.4 vs
196.41 ng $ h/mL in LTRs). However, as reported
by product characteristics, LCP-TAC presents an oral
bioavailability of approximately 30% higher than TAC-IR in
KTx recipients. The Cmax of LCP-TAC is signiﬁcantly lower
than TAC-IR in KTRs and LTRs (KTRs, 12.6 vs 17.6 ng/mL
[P < .0001]; LTRs, 11.8 vs 16.8 ng/mL [P < .001]), although
the median trough level (Cmin) was similar in KTRs (6.5 vs
6.8 ng/mL) and LTRs (5.9 vs 6.4 ng/mL). Consequently,
LCP-TAC has a signiﬁcant reduction of Cmax/Cmin ﬂuctua-
tion ratio, comparing with TAC-IR, (KTRs, 2.03 vs 2.75
[P < .0001]; LTRs, 2.1 vs 2.7 [P < .001]).
Because LCP-TAC is a prolonged-release formulation of
TAC, it results an extended oral absorption proﬁle with a
median time to maximum blood concentration (Tmax) of
approximately 6 hours at steady state, compared with 1.8 hours
of TAC-IR in KTRs (P < .0001) and 1.5 hours of TAC-IR in
LTRs(P< .001).Thedifferencesbetweenbloodconcentrations
versus time of LCP-TAC and TAC-IR are presented in Fig 1.
A very interesting innovation is that, in KTRs and LTRs,
the mean total daily dose of LCP-TAC is approximately
30% lower than that of TAC-IR to reach the same exposure
levels at 7 days. Moreover, there is a good correlation
between Cmin and AUC0e12 at steady-state for LCP-TAC inKRTs (r ¼ 0.91) and LTRs (r ¼ .94), making therapeutic
drug monitoring is possible with Cmin.
The blood sampling time must be in the morning before
administration. LCP-TAC should generally be taken on an
empty stomach to achieve maximal absorption. The other
pharmacokinetics steps are stackable and have no signiﬁcant
differences compared with TAC-IR. TAC has a biphasic
distribution and is extensively distributed. The steady-state
volume of distribution of TAC is 47.6 L in healthy volun-
teers. TAC crosses the placenta and is excreted in breast milk.
TAC is metabolized in the liver by cytochrome P450 3A4 and
in the intestinal wall. The metabolites do not contribute to its
pharmacologic activity in patients. The average total body
clearance of TAC is 2.25 L/h in healthy volunteers and was
6.7 L/h in adult KTx recipients, with a mean half-life of
approximately 30 hours in healthy volunteers.DISCUSSION
TAC is a calcineurin inhibitor much more potent than
cyclosporine, but its bioavailability is low and variable,
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The LCP-TAC uses a MeltDose technology and repre-
sents an innovation in the ﬁeld of the immunosuppressive
drugs. This new technology increases the amount of active
ingredient that reaches the blood, ensuring the best thera-
peutic efﬁcacy. Furthermore, the controlled release ensures
a continuous absorption not only in the duodenum but also
in the whole intestine, as demonstrated by Nigro et al. [11].
They studied a bowel scintigraphy immediately after dosing
of LCP-TAC. Drug dissolution begins in the stomach and/or
in the proximal part of the small intestine (time 0:02 hours),
about 11 hours after the drug is found in ascending and
transverse colon, and after 28 hours dissolution goes on in
the transverse and descending colon. This new formulation
of TAC ensures a continuous and consistent absorption
through the gastrointestinal tract for 24 hours.
In a phase II study conducted on KTx stable recipients,
there was a difference between blood concentrations of
TAC after administration of TAC-IR BID regimen, ob-
tained after 7 days after transplantation, and LCP-TAC QD
under after 14 and 21 days after transplantation [12]. From
a pharmacokinetic point of view, the following points pre-
sent signiﬁcant differences: (1) the total daily dosage (mg/d)
is lower, the Cmax is reduced with Tmax delayed, the swing
Cmax/Cmin is lower for LCP-TAC; (2) the Cmin is comparable
as well as the AUC0e24 between TAC-IR and LCP-TAC;
and (3) there is a good correlation between the Cmin and
the AUC0e24 (r
2 ¼ 0.86).
In a phase II study conducted on LTRs stable patients,
pharmacokinetic data demonstrated consistent exposure
(AUC) at the lower conversion dose. The Cmax, Cmax/Cmin
ratio, percent ﬂuctuation and swing were signiﬁcantly (P <
.001) lower and Tmax signiﬁcantly lower (P < .001) for
LCP-TAC versus TAC-IR [13].
In a 2014 paper by Grinyo et al. [14], the adjusted 1-year
cumulative dose was statistically reduced for LCP-TAC
compared with TAC-IR. The authors concluded that LCP-
TAC signiﬁcantly reduces the number of doses in the
short and long term, with signiﬁcant cost savings [14]. If
used an ofﬁcial deﬁned dial dose of TAC (IR and PR) and
conversion rate of LCP-TACs (1 mg:0.7 mg) as the summary
of product characteristics authorized by the European
Medicines Agency, and LCP-TAC price is similar to TAC-
PR cost, LCP-TAC therapy will cost less than TAC-PR. It
is important to remember that many hospitals negotiate
discounts on immunosuppressant drugs and competitive
tendering processes are often in place for the various for-
mulations and brands of TAC.
In a study by Bunnapradist et al. [15], the authors, on 162
stable KTx patients, found evidence of graft protection after 1
year of treatment with either TAC or LCP-TAC. The average
trough concentration did not differ between the 2 treatments
at 12 months (LCP-TAC, 5.19 vs TAC 5.07 ng/mL). However,
the cumulative dose at 12 months was signiﬁcantly lower (4.5
vs 4.8 for QD in BID; P < .001) [15].
The dosage should be based on clinical assessments
(rejection and tolerability) and whole-blood TACconcentration monitoring. The therapeutic range is
5e20 ng/mL in de novo KTx recipients and 5e15 ng/mL in
subsequent maintenance therapy (5e10 ng/mL, with
concomitant treatment). The recommended starting
dosage for TAC-PR in de novo KTRs or LTRs is 0.17 or
0.11e0.13 mg/kg, respectively, once daily in the morning,
initiated within 24 hours of the completion of surgery [16].
Finally, allograft transplant patients maintained on TAC-
IR BID or TAC-SR QD requiring conversion to QD TAC-
PR should be converted on a 1:0.7 (mg:mg) total daily dose
basis and the dose titrated against trough whole blood drug
concentration. This difference reﬂects the higher bioavail-
ability of TAC from LCP-TAC compared with TAC-IR such
that doses of LCP-TAC that achieve the same whole blood
trough concentrations at the end of the treatment period
(and are therapeutically equivalent) are approximately 30%
lower compared with TAC-IR.
In conclusion, LCP-TAC used in KTx and LTx trans-
plants, compared with other formulations of TAC, shows (1)
increased bioavailability, (2) a Cmin and AUC0e12 compa-
rable with TAC-IR and TAC-PR, (3) lower Cmax with lower
ﬂuctuations in blood concentrations; and (4) the cumulative
dose was lower than TAC-IR and TAC-PR. This new
technology represents a fundamental innovation in the ﬁeld
of immunosuppressants and will be tested in other types of
transplants. Obviously more studies must be done to
conﬁrm these results.REFERENCES
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